Regeneron pins hope on eczema drug as Eylea sales slow

(Reuters) - Regeneron Pharmaceuticals Inc Chief Executive Leonard Schleifer signaled that the U.S. biotech was on track to reduce its reliance on its flagship drug Eylea, as the company awaits the approval of two potential blockbuster treatments.

Source: Reuters: Health - February 9, 2017 Category: Consumer Health News Tags: healthNews Source Type: news